Fenofibrate / simvastatin benefit in dyslipidemia explored

Fenofibrate/Simvastatin benefit in dyslipidemia explored
Combination treatment with fenofibrate and simvastatin significantly reduces postprandial triglyceride levels compared with simvastatin alone in all subjects, regardless of fasting triglyceride level, but reduces atherogenic apolipoprotein B48 particles only in those with increased fasting triglyceride levels, according to research published online Oct. 25 in Diabetes Care.

(HealthDay)—Combination treatment with fenofibrate and simvastatin (FENO-S) significantly reduces postprandial (PP) triglyceride (TG) levels compared with simvastatin alone in all subjects, regardless of fasting TG level, but reduces atherogenic apolipoprotein (apo) B48 particles only in those with increased fasting TG levels, according to research published online Oct. 25 in Diabetes Care.

Gissette Reyes-Soffer, M.D., of the Columbia University Medical Center in New York City, and colleagues conducted a study involving a subset of 139 subjects (mean age, 61 years) from the Action to Control in Diabetes lipid study (ACCORD Lipid) to evaluate the effect of combination therapy with FENO-S compared with placebo plus (PL-S) on PP lipid and lipoprotein levels. Primary measures included PP plasma TG, apoB48, and apoCIII, measured over 10 hours after an oral fat load.

The researchers found that the PP TG incremental area under the curve (IAUC) above fasting was 572 and 770 in the FENO-S and PL-S groups, respectively (P = 0.008). In the FENO-S versus the PL-S group, there was a significant reduction in PP apoB48 IAUC. On the day of the study, fasting TG levels correlated with PP TG IAUC for both FENO-S and PL-S groups. For PP TG IAUC, the fibrate effect was constant across the range of fasting TG levels, while for PP apoB48 IAUC, the reduction was only seen when fasting TG levels were increased.

"These results may have implications for interpretation of the overall ACCORD Lipid trial, which suggested benefit from FENO-S only in dyslipidemic individuals," the authors write.

One author disclosed to and Merck Pharmaceuticals, both of which provided the study medications for the ACCORD Lipid trial.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

The Homburg Cream and Sugar study

Aug 29, 2011

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction ...

Mapping the genetic locus for triglycerides

Apr 25, 2008

Researchers have mapped out a region on human chromosome 1 that contributes to genetically elevated blood triglyceride levels, a major risk factor for heart disease.

Ionophore reverses Alzheimer's within days in mouse models

Jul 09, 2008

Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that a ...

Recommended for you

Mechanism behind age-dependent diabetes discovered

58 minutes ago

Ageing of insulin-secreting cells is coupled to a progressive decline in signal transduction and insulin release, according to a recent study by researchers at Karolinska Institutet in Sweden. The finding, ...

Pre-diabetes, diabetes rates fuel national health crisis

23 hours ago

Americans are getting fatter, and older. These converging trends are putting the USA on the path to an alarming health crisis: Nearly half of adults have either pre-diabetes or diabetes, raising their risk of heart attacks, ...

User comments